Fig. 7.

Rev-erbα activation alleviated experimental colitis in mice. a Weight loss measurements of four groups of mice with DSS feeding. b DAI scores of four groups of mice with DSS feeding. In panels a and b, data are mean ± SD (n = 8). *P < 0.05 (t test). c Survival rates of SR9009-treated and control mice (log-rank test). d Colon lengths of four groups of mice treated with DSS. Colon length was assessed at the time of necropsy. e Representative micrographs of colon H&E staining. Scale bar = 100 µm. f Histopathological scores of four groups of mice treated with DSS. g MPO activities of mice colons on day 8. h qPCR analyses of Nlrp3, IL-1β, and IL-18 expressions in whole colon tissues of mice with colitis on day 8. i ELISA measurements of colonic IL-18 protein on day 8 after DSS feeding. j Western blotting of Nlrp3, IL-1β, and β-actin in PMs or colons from mice with colitis on day 8. Each western blot is representative of three independent experiments (statistical differences between blot density levels were analyzed by Mann–Whitney U test, Supplementary Figure 12). SR9009 (50 mg/kg) was administered to mice via intraperitoneal injection once daily at ZT8 for 7 days prior to DSS treatment, and SR9009 dosing was continued along with DSS treatment. In panels d, f–i, data are mean ± SD (n = 5 for WT, n = 8 for other groups). *P < 0.05 (t test or Mann–Whitney U test). SR: SR9009